Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.

@article{FourniZaluski1994DualIO,
  title={Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.},
  author={Marie-Claude Fourni{\'e}-Zaluski and Walter Gonzalez and Serge Turcaud and Isabelle Pham and B. Roques and J B Michel},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={1994},
  volume={91 9},
  pages={4072-6}
}
In the treatment of cardiovascular disease, it could be of therapeutic interest to associate the hypotensive effects due to the inhibition of angiotensin II formation with the diuretic and natriuretic responses induced by the protection of the endogenous atrial natriuretic peptide (ANP). Investigation of this hypothesis requires an orally active compound able to simultaneously inhibit angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP), which is involved in renal ANP metabolism… CONTINUE READING